For the quarter ending 2025-09-30, SLDB had -$77,569K decrease in cash & cash equivalents over the period. -$33,557K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -45,776 | -78,762 |
| Amortization of discount on available-for-sale securities | 327 | 800 |
| Equity-based compensation expense | 3,928 | 6,486 |
| Depreciation and amortization expense | 376 | 793 |
| Non-cash lease expense | 598 | 1,162 |
| Non-cash acquired in-process research and development | 0 | - |
| Change in fair value of derivative liabilities | -850 | -2,550 |
| Other | 294 | -55 |
| Prepaid expenses and other assets | -1,716 | 2,060 |
| Accounts payable | 3,697 | 467 |
| Operating lease liabilities | -443 | -848 |
| Accrued expenses and other liabilities | 2,203 | 1,695 |
| Net cash used in operating activities | -33,472 | -69,262 |
| Purchases of property and equipment | 85 | 503 |
| Proceeds from maturities of available-for-sale securities | -38,000 | -69,000 |
| Purchases of available-for-sale securities | 83,188 | 128,777 |
| Other | 0 | -85 |
| Net cash used in investing activities | -45,273 | -60,195 |
| Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions | 0 | 189,637 |
| Proceeds from issuance of common stock and pre-funded warrants in private placement | - | 0 |
| Payments of common stock and pre-funded warrants issuance costs in public offering | 0 | 1,681 |
| Payments of common stock and pre-funded warrants issuance costs in private placement | 0 | 0 |
| Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions | 1,419 | 246 |
| Proceeds from exercises of common stock options | 0 | 6 |
| Employee stock purchase plan purchases | 0 | 196 |
| Payments of principal portion of finance lease obligations | 243 | 277 |
| Net cash provided by financing activities | 1,176 | 188,127 |
| Net decrease in cash, cash equivalents, and restricted cash | -77,569 | 58,670 |
| Cash and cash equivalents at beginning of period | 82,187 | - |
| Cash and cash equivalents at end of period | 63,288 | - |
Solid Biosciences Inc. (SLDB)
Solid Biosciences Inc. (SLDB)